Understanding the BALANCE Model for GLP-1 Medications in Medicare and Medicaid

• by Meredith Freed, Juliette Cubanski, Elizabeth Williams

• April 22, 2026

The ‘velocity of obesity’ aims to show which nations are slowing an epidemic

• by Elizabeth Cooney

• May 13, 2026

The Lipitor Warning for GLP-1 Drugmakers

Pfizer’s Lipitor experience shows the structural risks that today’s GLP-1 innovators may soon face

• by Joe Renny

• March 23, 2026

• 8 min

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.

• by Amanda M. Guiraldelli, Piotr Alvarez, Koen Sandra

• January 26, 2026

• 17 min